Therefore, we examined whether ductal-neuroendocrine lineage plasticity in PDA could contribute to resistance to standard of care gemcitabine, consistent with our observation that PDA patients with > 5% CK + SYP + cells recurred more rapidly on gemcitabine adjuvant therapy (Fig. 1d). This evidence concerns the gene SYP and Patent ductus arteriosus.